Meiragtx Holdings Plc (MGTX)

$4.26

-0.14

(-3.18%)

Market is closed - opens 7 PM, 25 Jun 2024

Insights on Meiragtx Holdings Plc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 5.10M → 697.0K (in $), with an average decrease of 62.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 20.21M → -20.44M (in $), with an average decrease of 201.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 78.5% return, outperforming this stock by 116.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.4% return, outperforming this stock by 318.0%

Performance

  • $4.26
    $4.49
    $4.26
    downward going graph

    0.0%

    Downside

    Day's Volatility :5.12%

    Upside

    5.12%

    downward going graph
  • $3.49
    $7.60
    $4.26
    downward going graph

    18.08%

    Downside

    52 Weeks Volatility :54.08%

    Upside

    43.95%

    downward going graph

Returns

PeriodMeiragtx Holdings PlcSector (Health Care)Index (Russel 2000)
3 Months
-31.36%
0.9%
0.0%
6 Months
-38.46%
8.7%
0.0%
1 Year
-35.67%
11.2%
0.0%
3 Years
-72.64%
17.3%
-24.2%

Highlights

Market Capitalization
277.2M
Book Value
$1.89
Earnings Per Share (EPS)
-1.19
Wall Street Target Price
21.2
Profit Margin
0.0%
Operating Margin TTM
-6710.47%
Return On Assets TTM
-31.82%
Return On Equity TTM
-69.93%
Revenue TTM
11.4M
Revenue Per Share TTM
0.19
Quarterly Revenue Growth YOY
-79.10000000000001%
Gross Profit TTM
15.9M
EBITDA
-138.2M
Diluted Eps TTM
-1.19
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.64
EPS Estimate Next Year
1.64
EPS Estimate Current Quarter
-0.5
EPS Estimate Next Quarter
-0.49

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Meiragtx Holdings Plc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 397.65%

Current $4.26
Target $21.20

Technicals Summary

Sell

Neutral

Buy

Meiragtx Holdings Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Meiragtx Holdings Plc
Meiragtx Holdings Plc
-16.75%
-38.46%
-35.67%
-72.64%
-79.51%
Moderna, Inc.
Moderna, Inc.
-19.93%
37.06%
10.79%
-39.4%
850.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
6.92%
23.97%
34.26%
93.43%
236.95%
Novo Nordisk A/s
Novo Nordisk A/s
4.35%
38.25%
80.59%
245.4%
453.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.57%
14.98%
34.9%
144.2%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Meiragtx Holdings Plc
Meiragtx Holdings Plc
NA
NA
NA
-1.64
-0.7
-0.32
NA
1.89
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.7
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.93
30.93
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.78
49.78
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.61
30.61
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Meiragtx Holdings Plc
Meiragtx Holdings Plc
Buy
$277.2M
-79.51%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.5B
850.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.3B
236.95%
30.93
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$644.0B
453.56%
49.78
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.7B
158.93%
30.61
39.46%

Institutional Holdings

  • Perceptive Advisors LLC

    17.62%
  • Johnson & Johnson

    10.33%
  • Adage Capital Partners Gp LLC

    8.23%
  • Prosight Management, LP

    6.25%
  • 683 Capital Management LLC

    3.89%
  • BlackRock Inc

    3.40%

Company Information

meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.

Organization
Meiragtx Holdings Plc
Employees
402
CEO
Dr. Alexandria Forbes Ph.D.
Industry
Health Technology

FAQs